dc.contributor.author |
Samsa, Greg |
|
dc.contributor.author |
Matchar, David B |
|
dc.contributor.author |
Dolor, Rowena J |
|
dc.contributor.author |
Wiklund, Ingela |
|
dc.contributor.author |
Hedner, Ewa |
|
dc.contributor.author |
Wygant, Gail |
|
dc.contributor.author |
Hauch, Ole |
|
dc.contributor.author |
Marple, Cheryl Beadle |
|
dc.contributor.author |
Edwards, Roger |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2016-03-01T16:34:50Z |
|
dc.date.issued |
2004-05-06 |
|
dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/15132746 |
|
dc.identifier |
1477-7525-2-22 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/11676 |
|
dc.description.abstract |
BACKGROUND: Anticoagulation can reduce quality of life, and different models of anticoagulation
management might have different impacts on satisfaction with this component of medical
care. Yet, to our knowledge, there are no scales measuring quality of life and satisfaction
with anticoagulation that can be generalized across different models of anticoagulation
management. We describe the development and preliminary validation of such an instrument
- the Duke Anticoagulation Satisfaction Scale (DASS). METHODS: The DASS is a 25-item
scale addressing the (a) negative impacts of anticoagulation (limitations, hassles
and burdens); and (b) positive impacts of anticoagulation (confidence, reassurance,
satisfaction). Each item has 7 possible responses. The DASS was administered to 262
patients currently receiving oral anticoagulation. Scales measuring generic quality
of life, satisfaction with medical care, and tendency to provide socially desirable
responses were also administered. Statistical analysis included assessment of item
variability, internal consistency (Cronbach's alpha), scale structure (factor analysis),
and correlations between the DASS and demographic variables, clinical characteristics,
and scores on the above scales. A follow-up study of 105 additional patients assessed
test-retest reliability. RESULTS: 220 subjects answered all items. Ceiling and floor
effects were modest, and 25 of the 27 proposed items grouped into 2 factors (positive
impacts, negative impacts, this latter factor being potentially subdivided into limitations
versus hassles and burdens). Each factor had a high degree of internal consistency
(Cronbach's alpha 0.78-0.91). The limitations and hassles factors consistently correlated
with the SF-36 scales measuring generic quality of life, while the positive psychological
impact scale correlated with age and time on anticoagulation. The intra-class correlation
coefficient for test-retest reliability was 0.80. CONCLUSIONS: The DASS has demonstrated
reasonable psychometric properties to date. Further validation is ongoing. To the
degree that dissatisfaction with anticoagulation leads to decreased adherence, poorer
INR control, and poor clinical outcomes, the DASS has the potential to help identify
reasons for dissatisfaction (and positive satisfaction), and thus help to develop
interventions to break this cycle. As an instrument designed to be applicable across
multiple models of anticoagulation management, the DASS could be crucial in the scientific
comparison between those models of care.
|
|
dc.language |
eng |
|
dc.publisher |
Springer Science and Business Media LLC |
|
dc.relation.ispartof |
Health Qual Life Outcomes |
|
dc.relation.isversionof |
10.1186/1477-7525-2-22 |
|
dc.subject |
Administration, Oral |
|
dc.subject |
Aged |
|
dc.subject |
Anticoagulants |
|
dc.subject |
Cost of Illness |
|
dc.subject |
Female |
|
dc.subject |
Focus Groups |
|
dc.subject |
Hematologic Tests |
|
dc.subject |
Humans |
|
dc.subject |
Long-Term Care |
|
dc.subject |
Male |
|
dc.subject |
Middle Aged |
|
dc.subject |
Outpatients |
|
dc.subject |
Patient Compliance |
|
dc.subject |
Patient Satisfaction |
|
dc.subject |
Psychometrics |
|
dc.subject |
Quality of Life |
|
dc.subject |
Sickness Impact Profile |
|
dc.subject |
Warfarin |
|
dc.title |
A new instrument for measuring anticoagulation-related quality of life: development
and preliminary validation.
|
|
dc.type |
Journal article |
|
duke.contributor.id |
Samsa, Greg|0110490 |
|
duke.contributor.id |
Matchar, David B|0063297 |
|
duke.contributor.id |
Dolor, Rowena J|0036012 |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/15132746 |
|
pubs.begin-page |
22 |
|
pubs.organisational-group |
Basic Science Departments |
|
pubs.organisational-group |
Biostatistics & Bioinformatics |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Duke Cancer Institute |
|
pubs.organisational-group |
Duke Clinical Research Institute |
|
pubs.organisational-group |
Institutes and Centers |
|
pubs.organisational-group |
Medicine |
|
pubs.organisational-group |
Medicine, General Internal Medicine |
|
pubs.organisational-group |
Pathology |
|
pubs.organisational-group |
School of Medicine |
|
pubs.organisational-group |
Surgery |
|
pubs.organisational-group |
Surgery, Head and Neck Surgery and Communication Sciences |
|
pubs.publication-status |
Published online |
|
pubs.volume |
2 |
|
dc.identifier.eissn |
1477-7525 |
|
duke.contributor.orcid |
Matchar, David B|0000-0003-3020-2108 |
|
duke.contributor.orcid |
Dolor, Rowena J|0000-0001-7317-9468 |
|